GlassScriptPhysician profile
Alice Tran
NPI 1134792898
$3,090.19
in general payments reported to CMS, 2019-2025
31 companies · $49.80 in 2025
The $49.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $942 · 2022: $1,265 · 2023: $819 · 2024: $14.31 · 2025: $49.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $399.64 | 2021-2023 | Breztri, Fasenra |
| Novo Nordisk INC | $332.08 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $308.17 | 2021-2023 | Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $222.55 | 2022-2023 | |
| Glaxosmithkline, LLC. | $209.24 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $126.06 | 2021 | |
| Amgen INC. | $123.80 | 2021-2023 | Prolia, Evenity, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.02 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.92 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $79.71 | 2021-2023 | Linzess |
| Amarin Pharma, INC. | $71.68 | 2021-2022 | |
| Bausch Health US, LLC | $71.25 | 2022-2023 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $67.17 | 2023 | Spravato |
| Eisai INC. | $60.89 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $58.57 | 2022-2023 | Seglentis |
| Sunovion Pharmaceuticals INC. | $54.90 | 2022 | |
| Pfizer INC. | $45.19 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $29.93 | 2023 | |
| Currax Pharmaceuticals LLC | $28.40 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $21.39 | 2022 | |
| Esperion Therapeutics, INC. | $21.18 | 2021 | |
| Astellas Pharma US INC | $20.18 | 2022 | |
| Gilead Sciences, INC. | $19.74 | 2023 | |
| Linus Health, INC. | $18.91 | 2023 | |
| Dexcom, INC. | $18.03 | 2022 | |
| Genentech USA, INC. | $17.36 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.20 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.03 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.40 | 2023 | Quviviq |
| Medicure Pharma INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.